Cetera Investment Advisers Sells 59,212 Shares of Haleon plc (NYSE:HLN)

Cetera Investment Advisers reduced its position in Haleon plc (NYSE:HLN - Free Report) by 25.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 174,576 shares of the company's stock after selling 59,212 shares during the period. Cetera Investment Advisers' holdings in Haleon were worth $1,442,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of HLN. Cultivar Capital Inc. acquired a new stake in Haleon during the second quarter worth approximately $40,000. Allspring Global Investments Holdings LLC bought a new position in shares of Haleon during the first quarter worth approximately $43,000. GAMMA Investing LLC increased its holdings in shares of Haleon by 151.3% during the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company's stock worth $52,000 after purchasing an additional 3,676 shares during the period. Pinnacle Bancorp Inc. increased its stake in Haleon by 29.8% in the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company's stock valued at $53,000 after acquiring an additional 1,421 shares during the last quarter. Finally, Hexagon Capital Partners LLC increased its stake in Haleon by 66.6% in the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company's stock valued at $55,000 after acquiring an additional 2,677 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HLN shares. UBS Group raised shares of Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. Berenberg Bank initiated coverage on shares of Haleon in a research note on Tuesday, August 6th. They issued a "buy" rating on the stock. Morgan Stanley boosted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a research note on Friday, September 20th. Finally, The Goldman Sachs Group cut shares of Haleon from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $10.95.

Haleon Stock Up 0.8 %

Shares of NYSE HLN traded up $0.08 during trading on Wednesday, hitting $10.10. 855,419 shares of the company traded hands, compared to its average volume of 5,214,781. The business's fifty day moving average is $10.19 and its 200 day moving average is $9.11. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $10.80. The firm has a market capitalization of $46.12 billion, a price-to-earnings ratio of 33.40, a P/E/G ratio of 2.93 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same period in the previous year, the firm earned $0.08 earnings per share. Equities research analysts predict that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were paid a $0.0514 dividend. This represents a yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon's payout ratio is 33.33%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.